Questionnaire

1. The InRange trial, using CGM-monitoring of TIR in adults with T1DM, demonstrated that compared with iDeg, Gla-300:

2. Studies comparing CGM and SMBG have demonstrated:

3. The BRIGHT study demonstrated that in adults with uncontrolled T2DM, participants randomised to Gla-300 (vs iDeg) experienced statistically significantly less anytime and nocturnal hypoglycaemia:

4. Factor(s) that contribute to therapeutic inertia in the management of T2DM are:

5. Regarding patients with diabetes and DKD:

6. When added to metformin in the GRADE trial, glucose-lowering agents that were found to be significantly more effective for achieving and maintaining target HbA_1c levels were:

7. An important first-line cost-effective glucose-lowering agent that is safe and efficacious in patients with DKD is:

8. Early combination therapy provides better glycaemic durability than a traditional stepwise treatment approach in newly diagnosed T2DM:

9. Lower rates of documented symptomatic hypoglycaemia with Gla-300 vs Gla-100 were observed in SENIOR study participants aged:

This questionnaire saves your responses automatically every 20 seconds if you are interrupted while answering.

10. In primary care practice, it is important to:

11. A systematic review and meta-analysis of CGM in adults with T2DM found improved glycaemic control compared with SMBG:

12. Limitations of using HbA1c for assessing glucose control include its:

13. The second leading cause of death in patients with diabetes and DKD is:

14. In terms of comorbid diabetes and DKD, KDIGO recommend a less aggressive HbA_1c target of 8.0% for those patients:

15. The BRIGHT study demonstrated greater HbA_1c reductions for iDeg than Gla-300 in patients with moderate-to-severe renal impairment: